Crappy drugs that only slow the decline a bit might need an aducanumab comparison, but why would a drug that reverses the decline need that?
See Cassava’s trial results.
See also this clinical trial of Bredesen’s approach (press release here).
Crappy drugs that only slow the decline a bit might need an aducanumab comparison, but why would a drug that reverses the decline need that?
See Cassava’s trial results.
See also this clinical trial of Bredesen’s approach (press release here).